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Background: Cryptococcal meningitis (CM) is a leading cause of mortality among HIV-infected individuals in Africa.
Poor outcomes from conventional antifungal therapies, unavailability of flucytosine, and difficulties administering
14 days of amphotericin B are key drivers of this mortality. Novel treatment regimes are needed. This study
examines whether short-course high-dose liposomal amphotericin B (AmBisome), given with high dose fluconazole,
is non-inferior (in terms of microbiological and clinical endpoints) to standard-dose 14-day courses of AmBisome
plus high dose fluconazole for treatment of HIV-associated CM.
Methodology/design: This is an adaptive open-label phase II/III randomised non-inferiority trial comparing
alternative short course AmBisome regimens. Step 1 (phase II) will compare four treatment arms in 160 adult
patients (≥18 years old) with a first episode of HIV-associated CM, using early fungicidal activity (EFA) as the primary
outcome: 1) AmBisome 10 mg/kg day one (single dose); 2) AmBisome 10 mg/kg day one and AmBisome 5 mg/kg day
three (two doses); 3) AmBisome 10 mg/kg day one, and AmBisome 5 mg/kg days three and seven (three doses); and
4) AmBisome 3 mg/kg/d for 14 days (control); all given with fluconazole 1200 mg daily for 14 days. STEP 2 (phase III)
will enrol 300 participants and compare two treatment arms using all-cause mortality within 70 days as the primary
outcome: 1) the shortest course AmBisome regimen found to be non-inferior in terms of EFA to the 14-day control
arm in STEP 1, and 2) AmBisome 3 mg/kg/d for 14 days (control), both given with fluconazole 1200 mg daily for
14 days. STEP 2 analysis will include all patients from STEP 1 and STEP 2 taking the STEP 2 regimens. All patients will be
followed for ten weeks, and mortality and safety data recorded. All patients will receive consolidation therapy with
fluconazole 400–800 mg daily and ART in accordance with local guidelines. The primary analysis (for both STEP 1 and
STEP 2) will be intention-to-treat.
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Cryptococcal meningitis is a major cause of death in
Sub-Saharan Africa, causing 10–20 % of all deaths in
HIV infected cohorts, resulting in up to 500,000 deaths
annually [1]. The poor outcomes reported using cur-
rently available antifungal therapy in African centres are
a critical driver of this high mortality [2–6], and provide
the impetus to develop novel treatment regimens for
cryptococcal meningitis. Prior studies demonstrate the
need for rapid initial clearance of cryptococcal infection
for survival [2]. Conventional amphotericin B deoxycho-
late (AmB-d) induction for 2 weeks, given with oral flu-
cytosine (5FC), is rapidly effective and still the gold
standard [7–10], but safe delivery is not feasible or sus-
tainable in most centres in Africa due to the need for
2 weeks hospitalisation and intravenous (iv) access, the
cost of extra iv fluids and electrolytes, and above all, the
availability and costs of rapid, reliable laboratory moni-
toring. Phlebitis with secondary infection [11], renal im-
pairment, and anaemia are also significant problems
with 14 days induction therapy with conventional AmB-
d. Flucytosine is prohibitively expensive and not avail-
able in Africa [12, 13]. The alternative treatment, oral
fluconazole, even at a dosage up to 1200 mg/d, as used
currently in many centres in Africa, is still much less
rapidly fungicidal than AmB-d, and mortality at 10 weeks
remains in excess of 50 % [5, 14, 15].
In recent studies, using shorter-course conventional
AmB-d (5–7 days) with high dose fluconazole [16, 17],
no slowing of the rate of clearance of infection over the
first 14 days was seen compared with 14 days of AmB-d,
and there was a large gain in tolerability and therefore,
ability to implement. The sustained effect of short-
course AmB-d may be related to its prolonged mean
residence time in brain tissue [18], and animal models
suggest that abbreviated regimens of AmB-d (as short as
3 days) are as effective as full 14-day courses (Fig. 1)
[18]. These data support the concept of short but still
highly effective induction regimens.
However, liposomal amphotericin B (AmBisome) would
be even more suitable for this strategy than conventional
AmB-d: it is less nephrotoxic, allowing much higher doses
to be given safely, and also has excellent tissue penetration
[19] and a long tissue half-life [20–23], raising the possibil-
ity of delivering highly effective induction therapy with
very few (one to three) doses. Single doses of up to 15 mg/
kg have been safely given to patients [22], and doses of
10 mg/kg are routinely given and have been shown to be
efficacious for treatment of visceral leishmaniasis [24] and
other invasive fungal infections [25].
Although AmBisome is recommended as a first-line
agent for treating cryptococcal meningitis in several
national guidelines [9, 26], there is uncertainty about the
optimal dosing strategies [27]. Pharmacokinetic datafrom animal models [21] and humans [20] suggest that
increasing AmBisome dose from the currently recom-
mended 3–4 mg/kg may be required to facilitate safe,
easy to administer, and effective intermittent dosing regi-
mens and produce an antifungal effect that is as least as
good as standard daily therapy [21]. High-dose flucona-
zole could be started with AmBisome, given evidence
from randomised studies of an additive effect of high-
dose fluconazole with conventional AmB-d [8, 28, 29],
and to provide ongoing consolidation therapy.
Prior to any expanded access programme for AmBi-
some for cryptococcal infection, it is vital that we define
the most clinically effective and most cost-effective
schedules for its use. This study will provide the data
needed. We propose to initially use early fungicidal activ-
ity (EFA), a highly efficient method to reliably test alterna-
tive treatment schedules in relatively small numbers of
patients [2, 7, 14, 16, 17, 28, 30–34], to determine the fun-
gicidal activity of several short-course dosing regimens. In
addition to being a statistically powerful endpoint, EFA
had been consistently shown to be independently asso-
ciated with clinical outcome (Fig. 2) [2, 34]. After EFA
evaluation in 160 patients, EFA, safety data and clinical
efficacy data will be used to select the best performing
intermittent dosing arm for ongoing clinical endpoint
comparison with standard daily dosing. The principal
aim of this study is to examine whether short-course
high-dose AmBisome treatment, given with high-dose
fluconazole, is non-inferior in terms of both microbio-
logical and clinical endpoints to standard-dose 14-day
courses of AmBisome plus high-dose fluconazole.
Method/design
Study design
This is an adaptive open label phase II/III randomised
non-inferiority trial to compare alternative short course
AmBisome regimens for the treatment of HIV-
associated cryptococcal meningitis.
Main hypothesis
Short-course high-dose AmBisome given with high dose
fluconazole will be non-inferior to 2 weeks of daily dosed
AmBisome-based induction therapy for the treatment of
HIV-associated cryptococcal meningitis.
Objectives
In step I (phase II), the primary objective is to determine
the EFA of three alternative schedules of intermittent
high-dose AmBisome in comparison with standard daily
AmBisome, all given with fluconazole at 1,200 mg/d for
the first 2 weeks, in induction therapy for HIV-associated
cryptococcal meningitis. Secondary objectives are to deter-
mine the pharmacokinetic (PK) parameters and PK/phar-
macodynamic (PD) associations of alternative schedules of
Fig. 1 The effect of various regimens of amphotericin B for experimental cryptococcal meningoencephalitis. Amphotericin B deoxycholate 1 mg/kg
was administered daily (b), every third day (c), as an abbreviated regimen for 3 consecutive days (d) and once (e). The solid arrows show the time of
drug administration. The data in a-e represent the time course of infection in the cerebrospinal fluid (CSF). Each line represents the fungal burden in
an individual rabbit. f shows the fungal density in the cerebrum at the end of the experiment. Each bar represents the mean fungal density ± standard
error of the mean. There is no statistically significant difference in the cerebral fungal density of rabbits receiving daily therapy versus those receiving
an abbreviated regimen of 1 mg/kg at 48, 72 and 96 h relative to inoculation: *p = 1.00 (not significant), **p = 0.006, ***p = <0.001, ****p = <0.001,
*****p = 1.00 (not significant). CFU, colony-forming units. From Livermore J, Howard SJ, Sharp AD, et al. Efficacy of an abbreviated induction regimen of
amphotericin B deoxycholate for cryptococcal meningoencephalitis: 3 days of therapy is equivalent to 14 days. MBio 2013; 5 (1): e00725-13.
With permission
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clinical efficacy and safety of these alternative schedules of
intermittent high-dose AmBisome in induction therapy
for HIV-associated cryptococcal meningitis and to modelthe cost-effectiveness of these alternative schedules of
intermittent high-dose AmBisome in induction therapy
for HIV-associated cryptococcal meningitis. In step II
(phase III), which includes transitioning to a phase III
Fig. 2 Early fungicidal activity and mortality. The left hand panel shows the crude mortality rate (per person year) calculated over the first
2 weeks of treatment according to early fungicidal activity (EFA) in the 450 patients of the 501 anti-retroviral therapy (ART)-naive patients recruited
in the studies listed in Reference 2 with slope (EFA) data. Patients have been stratified by EFA, with the slowest rate of clearance being 0–0.1
log10CFU/ml/day (equating to a 0 to 0.1 log drop in colony-forming units (CFU) per ml of cerebrospinal fluid (CSF) per day) and the highest rate
of clearance being 0.5+ (equating to a half-log10 drop or more in CFU counts/ml of CSF per day). The right hand panel shows Kaplan Meier
survival curves for the 501 ART-naive patients recruited into the studies listed in Reference 2 over the first 10 weeks of treatment, stratified by
EFA. The slowest rates of clearance are indicated by the solid black line (EFA 0–0.1 decline in log10CFU/ml/day) and the most rapid rates of
clearance are indicated by the small dotted line (EFA >0.3 decline in log10CFU/ml/day)
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step 1 meeting predefined minimum safety and efficacy
standards with standard daily AmBisome dosing, the pri-
mary objective is to determine mortality within the first
10 weeks using short course high-dose AmBisome in
comparison with standard daily AmBisome (for 14 days)
for induction therapy of HIV-associated cryptococcal
meningitis, both given with fluconazole at 1,200 mg/d for
the first 2 weeks. Secondary objectives are to determine
the EFA of alternative AmBisome schedules and culture
status at 2 weeks, to examine the proportions of patients
in each arm suffering clinical and laboratory-defined grade
III/IV adverse events; median percentage change from
baseline in laboratory-defined parameters by treatment
arm and to determine health service costs by treatment
arm.
Setting
Step 1 will be carried out in Princess Marina Hospital
(PMH), Gaborone, Botswana, which is a 500-bed tertiary
care hospital in the capital city, and Bugando Medical
Centre (with Sékou Touré Hospital and Butimba Hos-
pital), Mwanza, Tanzania, which is the referral and
teaching hospital for the Lake and Western zones of
Tanzania, serving a population of 13 million. Step 2 will
include the above plus Ifakara Health Institute, St
Francis Referral Hospital, Ifakara, Tanzania, a 370-bed
principal health care facility in the Kilombero district,
Morogoro region, serving a catchment area of 400,000people; Khayelitsha Hospital, with 150 adult beds, situ-
ated in the area with the highest HIV prevalence in the
Western Cape, South Africa; and the Parirenyatwa
General Hospital (Harare, Zimbabwe), which is one of the
largest tertiary academic teaching hospitals in Zimbabwe
and is affiliated with the University of Zimbabwe College
of Health Sciences. A further southern African site is still
to be confirmed.
Outcome measures
In step 1 the primary outcome measure is EFA with al-
ternative AmBisome schedules, and the secondary out-
come measures include mortality at 2 and 10 weeks and
time to death by treatment arm, unadjusted and adjusted
for possible confounders and PK and PK/PD parameters.
The PK-PD data will be modelled using population
methodology, enabling a robust estimate of drug expos-
ure in each patient, which can then be related to the ob-
served pharmacodynamic data (e.g., the rate of decline
in fungal density, or the time to undetectable cultures).
Proportions of patients in each arm suffering clinical
and laboratory-defined grade III/IV adverse events, and
median percentage change from baseline in laboratory-
defined parameters by treatment arm, and health service
costs by treatment arm, will be determined. In step 2 the
primary outcome measure will be mortality within
10 weeks by treatment arm. Secondary analysis will be
performed with adjustment for possible confounders.
EFA with alternative AmBisome schedules and culture
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suffering clinical and laboratory-defined grade III/IV ad-
verse events, median percentage change from baseline in
laboratory-defined parameters, and health service costs,
will be evaluated by treatment arm as secondary out-
come measures.
Sample size
Step 1: using a non-inferiority design, assuming an EFA
of 0.50 log colony forming units (CFU)/d, with standard
deviation of 0.25 in the standard daily dosing control
arm, an acceptable delta of 0.2, one-sided alpha of 0.025
and 90 % power, gives a sample size of 33 patients per
arm. A total sample of 40 patients per arm (160 patients
in total) will therefore be planned to allow for patients
who die prior to having a second lumbar puncture (LP)
to allow for an EFA measurement. An interim analysis
will be done after 20 patients per arm to make adjust-
ments, if necessary, to the required sample size, or to
consider stopping one or more arms if any are found to
result in significantly lower EFA than the control arm
(p <0.05) and are deemed unlikely to meet the prede-
fined non-inferiority criteria outlined above if contin-
ued to completion.
Step 2: a non-inferiority design has been chosen for as-
sessment of the primary mortality endpoint, as a short
course of AmBisome is not expected to be superior to
the standard course, but is expected to have similar effi-
cacy, while being easier to administer, affordable, and
better tolerated. Using a non-inferiority design assuming
10-week mortality of 25 %, with an acceptable non-
inferiority margin of 15 %, one-sided α = 0.025 and 90 %
power, gives a sample size of 176 per arm. Using the 40
patients already recruited into each of the control arm
and the short-course AmBisome arm from step 1 chosen
for step 2, 136 additional patients per arm are required.
To allow for withdrawals and losses to follow up a sam-
ple size of 150 patients per arm is planned, giving a total
sample size for step 2 of 300 patients.
Choice of non-inferiority margin
Step 1: previous studies demonstrate that the EFA of
14-day high-dose amphotericin-based regimens is in the
region of 0.5 log CFU/d [31], and it is anticipated that
standard-dose AmBisome regimens will be similar. The
acceptable delta of 0.2 log CFU/d was selected on the
basis of combined EFA data from over 500 patients in-
cluded in prior studies (Fig. 2) suggesting that notable
increases in mortality are not seen until the EFA drops
below 0.3 log CFU/d.
Step 2: we anticipate that short-course AmBisome will
have the same 10-week mortality as standard 14-day
courses. A non-inferiority margin of 15 % below an as-
sumed efficacy of 75 % (based upon recent data fromSouth Africa and Botswana [3, 28, 35]) was considered
acceptable based on the clinical acceptability and feasi-
bility of the novel short-course regimens compared to
standard 14-day courses of AmBisome, the current lim-
ited availability of conventional Amphotericin B-based
treatments in much of Africa, reported treatment out-
comes with Amphotericin B monotherapy [36] and
high-dose fluconazole monotherapy in Africa [5, 14],
and considerations relating to achievable recruitment
rate projections. The Data Monitoring Committee
(DMC) will regularly review mortality data, and appro-
priate increases to sample size will be made should the
mortality in the control arm prove to be higher than
anticipated.
Inclusion and exclusion criteria
Patients to be included in the study are consecutive pa-
tients ≥18 years with a first episode of cryptococcal
meningitis confirmed by either India ink or cryptococcal
antigen test (CrAg) in the cerebrospinal fluid (CSF).
They should be known to be HIV positive or willing to
undertake an HIV test (which is positive) and agree to
participate in the study. Pregnant (confirmed by urinary
pregnancy test) or lactating patients, patients with a pre-
vious serious reaction to study drugs, or patients on an-
tifungal treatment for more than 48 h or concomitant
medication that is contraindicated with study drugs at
the time of assessment for enrolment in the study, will
be excluded. ART-naïve and experienced patients will be
enrolled.
Consent
Written informed consent to enter into the trial must be
obtained from participants, or in the case of those with
mental obtundation, from the patient’s guardian or a
person with legal responsibility, after explanation of the
aims, methods, benefits and potential hazards of the trial
and before any trial-specific procedures are performed
or any blood is taken for the trial. In the case of patients
with altered mental status enrolled into the study, con-
sent will be obtained as above as soon as the patient’s
mental status improves, with care taken to ensure they
understand that they are free to withdraw from the study
and if they do so this will not jeopardise their immediate
and future care. Participants who withdraw will revert to
standard of care at the recruiting site (usually amphoter-
icin B deoxycholate and fluconazole 800 mg daily for
2 weeks, or fluconazole 1,200 mg daily for 2 weeks). It
will be made completely and unambiguously clear that
the participant (or guardian) is free to refuse to partici-
pate in all or any aspect of the trial, at any time and for
any reason, without incurring any penalty or affecting
their treatment (or that of their guardian). Signed
consent forms will be kept by the investigator and
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given to the participant or family.
Allocation
Patients will be randomised individually using a computer-
generated programme. Randomisation lists and sealed
envelopes will be prepared by an independent statisti-
cian in advance and sent to the sites. Randomisation will
be stratified by abnormal mental status and ART status
on admission at each site to ensure equal numbers of
severely ill patients and patients on ART in each group.
An allocation ratio of 1:1 and block sizes of 8 will be
used. The study monitor will audit the randomization
and allocation concealment process to ensure there are
no violations [37].
Interventions
In step 1, the four arms of the intervention are AmBisome
10 mg/kg on day 1 (single dose), AmBisome 10 mg/kg on
day 1, AmBisome 5 mg/kg on day 3 (two doses), AmBi-
some 10 mg/kg on day 1, AmBisome 5 mg/kg on days 3
and 7 (three doses), and AmBisome 3 mg/kg/d for 14 days,
which will act as the control (Fig. 3). In step 2 where the
interest is in clinical endpoints, the intervention will be
use of the shortest-course AmBisome regimen tested in
step 1 (either regimen 1, 2 or 3 above) meeting the prede-
fined safety and efficacy criteria and selected by the Trial
Steering Committee (TSC) for further study, and AmBi-
some 3 mg/kg/d for 14 days used as the control. Note that
all patients also receive fluconazole 1,200 mg/d for the
first 2 weeks, followed by 800 mg/d until 10 weeks, and
200 mg/d thereafter. ART will be commenced 4 to 5 weeks
after initiation of antifungal therapy. The trial clinical team
is not blinded to treatment allocation, however, laboratory
personnel performing CFU counts are blinded to treat-
ment allocation.
Rescue medication
All patients will receive fluconazole from day 1 at
1200 mg/d for the first 2 weeks, making it very unlikely
that CSF CFU counts will rise after the day 3 LP [5, 6].
However, in view of the single-dose AmBisome arm and
to ensure that all patients receive effective induction
therapy, if CFU counts go up (by any amount) after day
3, i.e., on the day-7 or day-14 LP, then the patient will
switch to daily AmBisome (3 mg/kg/d) for 7 to 14 days
and until the CSF is sterile. Thus, all patients will be en-
sured effective induction therapy.
Schedule
Clinical response will be monitored daily for the first
2 weeks or until discharge (whichever is later), then on
follow up at 3, 4, 6 and 10 weeks after the start of ther-
apy. Every effort will be made (e.g., with mobiletelephone calls and financial help with travelling ex-
penses) to obtain accurate and complete follow-up data
for 10 weeks after the start of treatment. Particular at-
tention will be paid to ascertaining immune reconstitu-
tion reactions in ART-naïve patients after starting ART.
Five millilitres of blood will be collected on days 3, 5,
7, 10, 12, and 14 of the study for creatinine and electro-
lytes. Full blood count (FBC) and alanine transaminases
(ALT) will be obtained on days 7 and 14 of the study.
On the day of the visit to the study clinic (week 4), blood
will be drawn for creatinine, electrolytes, FBC and ALT.
An extra 2.5 ml of blood will be taken for PK studies at
the time of monitoring blood tests, on days 1 and 3 (ex-
cluding the single-dose arm) at the end of AmBisome in-
fusion, and then 3, 6, 8 and 24 h post infusion. Follow-
up CSF examinations will be performed on days 3, 7, 14
and 21 to determine opening pressure, quantitative fun-
gal culture (QCC), CSF for drug levels, and immune pa-
rameters. In a variation on prior EFA studies (LPs on
day 1, 7 and 14), in step 1 LP will be done at day 21 and
for day-14 and day-21 quantitative cultures, an extra
plate will be spread with 1 ml of undiluted CSF – this
will increase sensitivity tenfold, and may help differenti-
ate the duration of the effect of AmBisome on clearance
with alternative regimens. Cryptococcal clearance rates
will be calculated using a summary statistic for each pa-
tient, the rate of decrease in log CFU per ml CSF per
day derived from the slope of the linear regression of log
CFU against time for each patient. A linear regression
model will be used to compare mean rates of decline or
EFA for each experimental treatment, giving summary
differences with 95 % CI and significance levels. We will
adjust analyses for potential confounding factors, includ-
ing baseline fungal load. Note that follow-up CSF exami-
nations for study purposes in step 2 will be performed
on days 7 and 14 only.
Type of analysis
After data cleaning, analysis will proceed according to
the predesigned analysis plan. The primary analysis (for
both step 1 and step 2) will be intention-to-treat ana-
lysis. Note, in step 1, patients who die prior to day 3 will
not have EFA calculated and thus, will be censored from
EFA analysis (modified intention-to-treat analysis – prior
experience of over 500 patients studied using this
method suggests EFA data will be available in at least
90 % of patients). Linear regression models will be calcu-
lated for step 1. Mean rate of decrease in CSF crypto-
coccal CFU (EFA) will be the dependent variable and
treatment group (using the standard treatment arm as a
comparator) will be the primary independent variable.
The comparator groups will be compared to the stand-
ard treatment arm for non-inferiority using standard cri-
teria with an acceptable delta of 0.2 log10 CFU/ml/day.
Fig. 3 Trial schema. Trial entry, randomisation and treatment. ART anti-retroviral therapy, EFA early fungicidal activity, SAE serious
adverse event
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Following a crude analysis, adjusted analysis will be per-
formed including covariates that may influence outcome.
As per the crude analysis, comparator groups will be
compared to the standard treatment arm for non-
inferiority using standard criteria with an acceptable
delta of 0.2 log10 CFU/ml/day. Adjustment will be made
for baseline fungal burden, which has been found to be
associated with rate of clearance in previous studies, and
for CD4 cell count, giving summary differences with
95 % CI.
The decision about which regimen will be taken for-
ward from step 1 to step 2 will be taken by the TSC in
conjunction with the DMC, and will be based upon pre-
defined safety and minimal efficacy criteria laid down in
the full statistical analysis plan. Briefly the shortest-
course AmBisome regimen of: 1) AmBisome 10 mg/kg
on day 1 (single dose), 2) AmBisome 10 mg/kg on day 1,
AmBisome 5 mg/kg on day 3 (two doses), 3) AmBisome
10 mg/kg on day 1, AmBisome 5 mg/kg on days 3 and 7
(three doses), that demonstrates non-inferiority to the
control arm in step 1 (in terms of EFA as defined above)
will be considered for step 2. The ultimate decision will
also take into account accrued safety, efficacy and mor-
tality data and the results of PK/PD analysis. Whilst for-
mal non-inferiority testing of EFA from step 1 will be
the primary evidence used to inform the decision, the
final choice of treatment arm will be at the discretion of
the TSC.
Primary and secondary outcomes for step 1 and step 2
are as listed above. For step 2 the primary endpoint is
mortality within the first 10 weeks by treatment arm.
The two treatment groups will be compared using the
Cochran-Mantel-Haenszel test for categorical data. Pa-
tients lost to follow up will be censored in the initial
analysis. Sensitivity analysis in which all patients lost to
follow up are assumed to have died, and Cox regression
time-to-event analysis will be performed.
Dissemination of results
The results from the different centres will be analysed
together, published as soon as possible, and presented at
an international conference. Step 1 and step 2 will be
published in two separate reports. The Trial Manage-
ment Group (TMG) will form the basis of the Writing
Committee and will advise on the nature of the publica-
tion. The names of all investigators will be included in
the authorship of any publication. Any authorship policy
will be agreed by all investigators before the commence-
ment of the trial. The members of the TSC and DMC
will be listed with their affiliations in the acknowledge-
ments or appendix section of the main publication. The
funders will have no role in the decision to publish or
the content of the publication.Ethical approval
The Research Ethics Committees of the London School
of Hygiene and Tropical Medicine (6544–01), Botswana
MoH HRDC (PPME-13/18/1 Vol IX (6)), PMH IRB
(5/79/90a), and the University of Pennsylvania (820127)
have approved the protocol. We will not begin any recruit-
ment in any individual centre until local ethical approval
has been obtained. Any further amendments will be sub-
mitted and approved by each ethics committee.
Timeline
We anticipate that 60 patients will be enrolled in the
study in Botswana and 160 patients in Tanzania over a
2-year period. This is feasible based upon historical
numbers of admissions and previous studies at these
sites [3, 4, 6].
Ancillary studies
PK/PD and cost-effectiveness studies will be performed
as outlined in this protocol. Cryptococcal isolates will be
saved and shared with members of the cryptococcal re-
search community for ongoing phenotypic and molecu-
lar epidemiology studies. Blood and CSF samples will be
saved for ongoing studies examining the phenotype of
the immune response to cryptococcus, and the patho-
physiology of immune reconstitution inflammatory syn-
dromes. Blood will also be stored for future studies
determining how polymorphisms in immune response
genes relate to susceptibility to and outcomes from
cryptococcal meningitis. Any samples that require ship-
ment will be in accordance with the local Material
Transfer Agreement (MTA) guidelines.
Quality control and assurance
The study sponsor is St George’s University of London.
The sites will be visited at regular intervals in order to
monitor the conduct of the trial and ensure that the
principles of International Conference of Harmonisation
(ICH) good clinical practice (GCP) is being adhered to.
These visits will be made by the trial manager/monitor
from the sponsoring institution. The frequency of moni-
toring visits will be according to need but will be at least
after recruitment of the first 10 to 15 patients at each
site, and after recruitment of 50 % and 100 % of patients
(trial closure). If issues arise the frequency of visits will
be increased. Site initiation assessments will be con-
ducted at each site prior to trial initiation. The trial
manager will visit the sites and ensure that all training
(including GCP and protocol-specific training) has been
completed, that drug supply and equipment are in place
and that all study staff are up to date on the protocol
and procedures, and are competent to undertake the
roles described for them in the standard operating pro-
cedures (SOPs). An external audit by the London School
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ducted towards the beginning of the trial. Central moni-
toring will be performed in addition to the on-site
monitoring procedures. Cumulative monthly reports (in-
cluding information on recruitment rates, withdrawals,
losses to follow up) will be compiled by the trial man-
ager/statistician and reviewed by the TMG. Bimonthly
reports on grade III/IV adverse events (AEs)/serious ad-
verse events (SAEs)/serious adverse reactions (SARs)/
suspected unexpected serious adverse reaction (SUSARs)
will be compiled by the trial manager/statistician and
reviewed by the TMG.
Data collection and data management
Data will be managed using the Clinical DataFax System
(Infectious Diseases Institute, Uganda). The study teams
will directly enter data onto paper CRFs that will be la-
beled with unique patient identifiers. These will be
scanned and sent in real time to the DataFax Research
Unit, where data entry, verification and review will be
performed. Routine quality control checks will be in
place that will capture possible inconsistencies/missing
data in real time, allowing queries to be sent back weekly
to the study teams. Additionally, at monitoring visits the
data entered in the CRFs will be checked against avail-
able source data by the trial monitor/manager. Trial data
will be checked for missing or unusual values (range
checks) and checked for consistency. If any such prob-
lems are identified, any data that are changed will be
crossed through with a single line and initialled. Site in-
vestigators will not have access to cumulative data by
study arm. On completion of recruitment, data will be
securely exported from the DataFax database into the
Stata statistical package, and following data cleaning and
checking, the database will be locked and analysis will
proceed according to the predefined analysis plan.
Confidentiality
The principles of the UK Data Protection Act will be
followed regardless of the countries where the trial is be-
ing conducted. The study site records will contain
names, addresses, and contact details of the patients to
enable follow up of patients. Unique numeric identifiers
will be assigned to all patients, and only this unique
number will be included in data sent from the trial sites
and entered into the study database. The site investiga-
tor will ensure safekeeping of the patient data.
Termination of the study
The trial will be considered closed when the last patient
has completed 10 weeks in the study and all follow-up
and laboratory reports have been received. Early termin-
ation could occur if the DMC decides there is an un-
acceptable level of adverse events in any of the test arms.Indemnity
The sponsor of the trial is St George’s University of
London. All personnel involved in the trial will be ex-
pected to be indemnified by their employing authority.
Patients will be indemnified through the policy of the
trial sponsor. Local insurance will be taken out where
local regulations require this.
Discussion
The potential impact of a safe, sustainable regimen of
high-dose intermittent AmBisome of equivalent efficacy
to 2 weeks of daily Amphotericin-based induction (either
conventional or liposomal), would be to reduce 10-week
mortality in the majority of the African centres that still
rely on fluconazole monotherapy, from approximately
60 % [5, 6, 14] to the 20−40 % seen with Amphotericin B-
based combinations [2, 3]. It would also facilitate effective
treatment, reduce the duration of hospital admissions,
and lower the high burden of drug-related side effects cur-
rently seen in centres using conventional AmB-d based
therapy. A large reduction in the number of doses, and
duration of hospitalisation, together with reduced pricing
of AmBisome, may result in costs that are comparable, or
less than 2 weeks conventional AmB-d being given with
appropriate monitoring.
Trial status
The study is funded through a Gilead investigator initiated
award to the Chief Investigators (Professor Harrison
and Dr Jarvis). Funding for step 2 is to be confirmed.
Trial recruitment is due to start in December 2014
pending the requisite ethical and regulatory clearance.
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